|
|
HC Wainwright & Co. Maintains Buy on Evommune, Raises Price Target to $65
|
|
|
|
Evommune's Stock Surges On Strong Results For New Eczema Drug
|
|
|
|
Gold Moves Lower; CVS Health Earnings Top Views
|
|
|
|
12 Health Care Stocks Moving In Tuesday's Intraday Session
|
|
|
|
Datadog, Spotify, Marriott, Ferrari And Other Big Stocks Moving Higher On Tuesday
|
|
|
|
Dow Surges Over 200 Points; Coca-Cola Posts Mixed Q4 Results
|
|
|
|
Evommune shares are the company announced the top-line results for its Phase 2a trial evaluating EVO301 met its primary efficacy endpoint.
|
|
|
|
Evommune Reports Top-Line Results From Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial Evaluating EVO301; Trial Met Primary Efficacy Endpoint At Week 12
|
|
|
|
Oppenheimer Initiates Coverage On Evommune with Outperform Rating, Announces Price Target of $42
|
|